Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí hóa học quốc tế đề tài : Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study | Health and Quality of Life Outcomes BioMed Central Open Access Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms Results from a randomized controlled Phase III study Dennis A Revicki 1 Alan Menter2 Steven Feldman3 Miriam Kimel1 Neesha Harnam1 and Mary K Willian4 Address 1Center for Health Outcomes Research United BioSource Corporation Bethesda Maryland USA 2Division of Dermatology Baylor Research Institute Dallas TX USA 3Department of Dermatology Wake Forest University Baptist Medical Center Winston-Salem NC USA and 4Global Health Economics Outcomes Research Abbott Laboratories Abbott Park Illinois USA Email Dennis A Revicki - Alan Menter - amderm@ Steven Feldman - sfeldman@ Miriam Kimel - Neesha Harnam - Mary K Willian - Corresponding author Published 2 October 2008 Received I I April 2008 Health and Quality of Life Outcomes 2008 6 75 doi 1477-7525-6-75 Accepted 2 October 2008 This article is available from http content 6 1 75 2008 Revicki et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Objective To evaluate the impact of adalimumab on health-related quality of life HRQOL for patients with moderate to severe plaque psoriasis. Background Psoriasis is a chronic inflammatory immune-mediated disease that has a significant impact on patients HRQOL. Adalimumab is a fully human monoclonal antibody that blocks tumor necrosis factor a pro-inflammatory cytokine and is effective and well-tolerated for patients with moderate to severe psoriasis. .
